
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is expected to continue its strong growth in the MedTech industry, with an estimated 20% revenue CAGR and 20% EPS growth. Despite recent product recalls, the company remains confident in maintaining its leadership position in the expanding tubeless category and has a strong governance model, making it a potentially attractive investment for shareholders in the long term. However, competition and short-term concerns may limit immediate stock performance.
Bears say
Insulet is facing several challenges that could negatively impact their stock performance in the future. These include competition within the insulin pump market, potential supply chain disruptions, and delays in international expansion. Additionally, recent voluntary medical device corrections and a potential slowdown in patient starts could also lead to slower revenue and profitability growth. The current valuation for Insulet may not fully account for these risks, making it a risky investment at this time.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares